Equibles does not estimate personal net worth.
Get an email with a short summary when Milestone Pharmaceuticals Inc. publishes a filing, an earnings call transcript or a press release.
Get MIST alertsJoseph Oliveto is recorded as Board Member at Milestone Pharmaceuticals Inc. (MIST) since January 1, 2017 and CEO at Milestone Pharmaceuticals Inc. (MIST). The newest filing on record that lists Joseph Oliveto as CEO and Board Member at Milestone Pharmaceuticals Inc. (MIST) is dated April 30, 2026. Milestone Pharmaceuticals Inc. reported in an 8-K filed June 12, 2025 that Joseph Oliveto was appointed director, effective June 10, 2025. The proxy statement of Milestone Pharmaceuticals Inc. reports total compensation of $2,121,015 for Joseph Oliveto in fiscal 2025, including a base salary of $649,641. Disclosed compensation is on record for 8 fiscal years. Joseph Oliveto has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for Milestone Pharmaceuticals Inc. on September 8, 2026. Milestone Pharmaceuticals Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Milestone Pharmaceuticals Inc. includes Amit Hasija (CFO), Jeffrey Nelson (COO), David Sandoval (General Counsel) and 7 others.
“The Company’s shareholders elected the nominees below to the board of directors (the “Board”) each to hold office until the 2026 Annual Meeting of Shareholders, or until their successors are duly elected or appointed or until such directors’ earlier resignation or removal.”
“I appreciate all the colleagues at Wells Fargo for having us at this great conference.”
“Good morning, everyone, and thank you for joining us today to hear about our progress through the second quarter. Until this year, patients experiencing sudden attacks of paroxysmal supraventricular tachycardia, or PSVT, had no FDA-approved self-administered treatment available to them.”
“This is an exciting day as it represents our first analyst call reporting on our first-ever quarter, or more accurately, partial quarter, of sale since the commercial launch of Cardamus for acute episodes of paroxysmal supraventricular tachycardia, or PSVT.”
“December 2025 marked a transformational event for Milestone Pharmaceuticals with the FDA approval of Cardamist, a trypamil nasal spray for paroxysmal supraventricular tachycardia, or more specifically, for the conversion of PSVT to normal sinus rhythm in adults.”
2017-01-01–present
Last confirmed April 30, 2026
Start not stated–present
Last confirmed April 30, 2026
Biotechnology · Healthcare
CEO, Board Member
2017-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Milestone Pharmaceuticals Inc. (MIST) | Chief Executive Officer & President | $649,641 | $2,121,015 |
| 2024 | Milestone Pharmaceuticals Inc. (MIST) | Chief Executive Officer | $601,520 | $882,261 |
| 2023 | Milestone Pharmaceuticals Inc. (MIST) | Chief Executive Officer | $601,520 | $1,978,092 |
| 2022 | Milestone Pharmaceuticals Inc. (MIST) | Chief Executive Officer | $584,000 | $2,965,827 |
| 2021 | Milestone Pharmaceuticals Inc. (MIST) | Chief Executive Officer | $509,208 | $4,099,905 |
| 2020 | Milestone Pharmaceuticals Inc. (MIST) | Chief Executive Officer | $469,792 | $4,087,536 |
| 2019 | Milestone Pharmaceuticals Inc. (MIST) | Chief Executive Officer | $458,488 | $784,988 |
| 2018 | Milestone Pharmaceuticals Inc. (MIST) | Chief Executive Officer | $360,000 | $1,436,837 |
